Summary of the Company's Unaudited Quarterly Results of Operations |
The quarterly interim financial information shown below has been
prepared by the Company’s management and is unaudited. It
should be read in conjunction with the audited financial statements
appearing herein.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2017 |
|
|
|
First |
|
|
Second |
|
|
Third |
|
|
Fourth |
|
Revenues
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
Total operating expenses
|
|
|
1,987,656 |
|
|
|
1,396,759 |
|
|
|
1,921,520 |
|
|
|
1,412,383 |
|
Profit (loss) from discontinued operations
|
|
|
(121 |
) |
|
|
121 |
|
|
|
-0- |
|
|
|
— |
|
Net Loss
|
|
|
(1,982,696 |
) |
|
|
(1,220,866 |
) |
|
|
(2,067,230 |
) |
|
|
(1,460,733 |
) |
Loss per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted net loss per share from continuing operations
|
|
$ |
(0.40 |
) |
|
$ |
(0.25 |
) |
|
$ |
(0.42 |
) |
|
$ |
(0.30 |
) |
Basic and diluted net profit per share from discontinued
operations
|
|
$ |
0.00 |
|
|
$ |
0.00 |
|
|
$ |
0.00 |
|
|
$ |
0.00 |
|
|
|
|
|
2016 |
|
|
|
First(1) |
|
|
Second |
|
|
Third |
|
|
Fourth |
|
Revenues
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
Total operating expenses
|
|
|
2,074,645 |
|
|
|
1,733,282 |
|
|
|
2,026,670 |
|
|
|
2,707,908 |
|
Profit from discontinued operations
|
|
|
11,113 |
|
|
|
1,420,947 |
|
|
|
42,566 |
|
|
|
9,386 |
|
Net Loss
|
|
|
(2,062,885 |
) |
|
|
(312,615 |
) |
|
|
(1,963,007 |
) |
|
|
(2,674,797 |
) |
Loss per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted net loss per share from continuing operations
|
|
$ |
(0.52 |
) |
|
$ |
(0.43 |
) |
|
$ |
(0.41 |
) |
|
$ |
(0.55 |
) |
Basic and diluted net profit per share from discontinued
operations
|
|
$ |
0.00 |
|
|
$ |
0.35 |
|
|
$ |
0.01 |
|
|
$ |
0.00 |
|
(1) |
Certain amounts previously reported
as revenue, cost of revenue, research and development, selling,
general and administrative relating to the consumer probiotic
business is now reported as profit (loss) from discontinued
operations. |
|